C

Checkpoint Therapeutics
D

CKPT

3.13000
USD
-0.05
(-1.57%)
مغلق
حجم التداول
24,988
الربح لكل سهم
-1
العائد الربحي
-
P/E
-2
حجم السوق
152,845,725
نظرة عامةالتوصياتالأفكار والتحليلاتالأخبار
أصول ذات صلة
    ABBV
    ABBV
    1.200
    (0.60%)
    202.140 USD
    AMGN
    AMGN
    5.10
    (1.71%)
    303.15 USD
    AZN
    AZN
    -0.350
    (-0.47%)
    74.220 USD
    BMY
    BMY
    0.050
    (0.09%)
    55.840 USD
    GSK
    GSK
    -0.320
    (-0.87%)
    36.650 USD
    JNJ
    JNJ
    2.680
    (1.68%)
    162.370 USD
    MRK
    MRK
    1.820
    (2.08%)
    89.500 USD
    NVS
    NVS
    2.100
    (1.96%)
    109.370 USD
    PFE
    PFE
    0.405
    (1.56%)
    26.305 USD
    SNY
    SNY
    0.325
    (0.60%)
    54.445 USD
    المزيد
الأخبار
المقالات

العنوان: Checkpoint Therapeutics

القطاع: Healthcare
الصناعة: Biotechnology
Checkpoint Therapeutics Inc is an immuno-oncology biopharmaceutical company based in the USA. It focuses on the acquisition, development, and commercialization of novel, non-chemotherapy, immune-enhanced combination treatments for patientswith solid tumor cancers. Its licensed portfolio of antibodies includes targeting programmed cell death-ligand 1 (PD-L1), glucocorticoid-induced TNFR-related protein (GITR) and carbonic anhydrase IX (CAIX). The company is evaluating its lead small-molecule, targeted anti-cancer agent, olafertinib, a third-generation epidermal growth factor receptor ("EGFR") inhibitor, as a potential new treatment for patients with EGFR mutation-positive non-small cell lung cancer.